OBJECTIVE: The aim of this study was to evaluate the tolerability of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS: This was a two-phase, 7-week, open study in children aged 6-17 years. Phase 1 initiated ATMX for a minimum of 4 weeks. Phase 2 entered partial responders to ATMX and added OROS MPH to their regimen. Safety was assessed using blood pressure and heart rate measurements, electrocardiogram readings, AEs, laboratories, and ATMX levels. RESULTS: Fifty subjects who were partial responders to ATMX received the combination therapy, with 41 subjects completing the entire protocol. As reported elsewhere (Wilens et al., 2009 ), OROS MPH added to partial responders of ATMX was accompanied by a 40% reduction in the ADHD rating scale score and improvements in executive functioning. However, the combination of ATMX plus OROS MPH was associated with greater rates of insomnia, irritability, and loss of appetite compared to ATMX alone. A small significant increase in diastolic blood pressure was observed during adjunctive OROS MPH, with no clinically meaningful changes in electrocardiogram (ECG) parameters during the study. ATMX levels and liver function tests did not significantly change during the combination treatment. CONCLUSION: Adjunct OROS MPH in ATMX partial responders yielded an additive adverse effect burden in this short-term study. Further controlled research with larger samples of children is warranted.
OBJECTIVE: The aim of this study was to evaluate the tolerability of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS: This was a two-phase, 7-week, open study in children aged 6-17 years. Phase 1 initiated ATMX for a minimum of 4 weeks. Phase 2 entered partial responders to ATMX and added OROS MPH to their regimen. Safety was assessed using blood pressure and heart rate measurements, electrocardiogram readings, AEs, laboratories, and ATMX levels. RESULTS: Fifty subjects who were partial responders to ATMX received the combination therapy, with 41 subjects completing the entire protocol. As reported elsewhere (Wilens et al., 2009 ), OROS MPH added to partial responders of ATMX was accompanied by a 40% reduction in the ADHD rating scale score and improvements in executive functioning. However, the combination of ATMX plus OROS MPH was associated with greater rates of insomnia, irritability, and loss of appetite compared to ATMX alone. A small significant increase in diastolic blood pressure was observed during adjunctive OROS MPH, with no clinically meaningful changes in electrocardiogram (ECG) parameters during the study. ATMX levels and liver function tests did not significantly change during the combination treatment. CONCLUSION: Adjunct OROS MPH in ATMX partial responders yielded an additive adverse effect burden in this short-term study. Further controlled research with larger samples of children is warranted.
Authors: H Gutgesell; D Atkins; R Barst; M Buck; W Franklin; R Humes; R Ringel; R Shaddy; K A Taubert Journal: J Am Acad Child Adolesc Psychiatry Date: 1999-08 Impact factor: 8.829
Authors: James J McGough; Keith McBurnett; Oscar Bukstein; Timothy E Wilens; Laurence Greenhill; Marc Lerner; Mark Stein Journal: J Child Adolesc Psychopharmacol Date: 2006-06 Impact factor: 2.576
Authors: Joachim F Wernicke; Douglas Faries; Donald Girod; Jeffrey Brown; Haitao Gao; Douglas Kelsey; Humberto Quintana; Robert Lipetz; David Michelson; John Heiligenstein Journal: Drug Saf Date: 2003 Impact factor: 5.606
Authors: Timothy E Wilens; Paul Hammerness; Linsey Utzinger; Mary Schillinger; Anna Georgiopoulous; Robert L Doyle; Marykate Martelon; Kerry Brodziak Journal: J Child Adolesc Psychopharmacol Date: 2009-10 Impact factor: 2.576
Authors: Timothy E Wilens; Paul Hammerness; Linsey Utzinger; Mary Schillinger; Anna Georgiopoulous; Robert L Doyle; Marykate Martelon; Kerry Brodziak Journal: J Child Adolesc Psychopharmacol Date: 2009-10 Impact factor: 2.576
Authors: Victoria A Reed; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David R Coghill; Ludmila A Kryzhanovskaya; Nicola C Savill Journal: CNS Drugs Date: 2016-07 Impact factor: 5.749
Authors: Tamás Treuer; Susan Shur-Fen Gau; Luis Méndez; William Montgomery; Julie A Monk; Murat Altin; Shenghu Wu; Chaucer C H Lin; Héctor J Dueñas Journal: J Child Adolesc Psychopharmacol Date: 2013-04-06 Impact factor: 2.576
Authors: Silviu Grisaru; Melissa Yue; Susan M Samuel; Kathleen H Chaput; Lorraine A Hamiwka Journal: Paediatr Child Health Date: 2018-03-05 Impact factor: 2.253